Lyndsey Crennen was named Chief Accounting Officer of Mesa Laboratories Inc /Co/. As of November 15, 2026, Mesa Laboratories Inc /Co/ has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from March 9, 2026 to June 15, 2026, naming 2 appointments and 2 departures (Form 8-K, June 15, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Mesa Laboratories Inc /Co/? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: In · Person: Lyndsey Crennen · Role: Chief Accounting Officer · 8-K, 2026-06-15
- · In / out: Out · Person: Gary Owens · Role: Director · Effective: 2026-03-20 · 8-K, 2026-03-23
- · In / out: Out · Person: Gary Owens · Role: President and Chief Executive Officer · 8-K, 2026-03-09
Mesa Laboratories Inc /Co/ reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-03-09 to 2026-06-15. They name 3 people, with 2 appointments and 2 departures. Every row below is cited to the filing it comes from, and this page adds each new change as Mesa Laboratories Inc /Co/ files it.
Layoffs on record: about 40 jobs, latest 2026-10-13 (layoff filings and notices).
Also on the record for Mesa Laboratories Inc /Co/
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 27, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 7.9% of the class | 5%+ stakes | Source |
| October 9, 2026 | Stake report, Schedule 13G, by Wasatch Advisors LP | 6.9% of the class | 5%+ stakes | Source |
| July 7, 2026 | Stake report, Schedule 13G/A, by Long Path Smaller Companies Fund, LP | 8.6% of the class | 5%+ stakes | Source |
| April 15, 2026 | Stake report, Schedule 13G/A, by Long Path Smaller Companies Fund, LP | 7.3% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| March 13, 2026 | Stake report, Schedule 13G, by Long Path Smaller Companies Fund, LP | 5.6% of the class | 5%+ stakes | Source |
| October 31, 2025 | Stake report, Schedule 13G/A, by The Vanguard Group | 5.84% of the class | 5%+ stakes | Source |
| October 2, 2025 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 6.9% of the class | 5%+ stakes | Source |
| July 18, 2025 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 14.4% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Mesa Laboratories Inc /Co/ now and the warning signs.
Free to see. No signup.
Keep reading
More on Mesa Laboratories Inc /Co/ and the records around it.
Mesa Laboratories Inc /Co/ elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- Wasatch Advisors LP also filed stake reports on 72 other companies: Smith Douglas Homes Corp (Oct 2026), Amtech Systems Inc (Oct 2026), BBB Foods Inc (Oct 2026)
- BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)
- The Vanguard Group also filed stake reports on 2385 other companies: BellRing Brands, Inc. (Sep 2026), CAL-MAINE FOODS INC (Sep 2026), FTAI Aviation Ltd. (Sep 2026)
Watch Mesa Laboratories Inc /Co/
Get an email when Mesa Laboratories Inc /Co/ files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Mesa Laboratories Inc /Co/?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Mesa Laboratories Inc /Co/: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Mesa Laboratories Inc /Co/ covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-06-15 | In | Chief Accounting Officer | 8-K, 2026-06-15 | ||
| 2026-03-23 | Out | Director | 2026-03-20 | 8-K, 2026-03-23 | |
| 2026-03-09 | Out | President and Chief Executive Officer | 8-K, 2026-03-09 | ||
| 2026-03-09 | In | President and Chief Executive Officer | 8-K, 2026-03-09 |
Why did they leave? What the filings say
For each named departures below, the sentence from the company's own filing that gives a reason, word for word. Where a filing gives none, it says so here; nothing is inferred.
- Gary Owens, Director (filed 2026-03-23):
Under the Transition Agreement, upon termination on the Separation Date, Mr. Owens will be entitled to receive the severance pay and benefits associated with a "without cause" termination based on his termination on the Separation Date and to retain a pro-rated portion of his June 15, 2025 performance stock unit award, which will vest at the lower of target or actual performance at the end of the performance period.
- Gary Owens, President and Chief Executive Officer (filed 2026-03-09):
Mr. Owens' separation from the Company is not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
Who leads Mesa Laboratories Inc /Co/, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Accounting Officer: Lyndsey Crennen, appointed (filed 2026-06-15).
- Director: Gary Owens, departure reported, effective 2026-03-20 (filed 2026-03-23). No successor is named in these filings.
- President and Chief Executive Officer: Gary Owens, departure reported (filed 2026-03-09). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Mesa Laboratories Inc /Co/: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Accounting Officer at Mesa Laboratories Inc /Co/, with the record behind each one.
Find candidates like Chief Accounting Officer at Mesa Laboratories Inc /Co/Every change, in the filing's words
Appointed: Lyndsey Crennen, Chief Accounting Officer
On June 11, 2026, the board of directors (the "Board") of Mesa Laboratories, Inc. ("Mesa" or the "Company") approved the appointment of Lyndsey Crennen as the Chief Accounting Officer of the Company, effective as of her entry into the Employment Agreement described below.
- Ms. Crennen, age 41, has over 20 years of experience in accounting and related roles.
- Ms. Crennen joined Mesa in 2018 as Assistant Controller and has held progressive accounting roles at the Company, including serving as Corporate Controller since 2022.
- Prior to joining Mesa, Ms. Crennen worked at Chipotle Mexican Grill, Inc., where she led the internal audit function from 2012 to 2014 and subsequently oversaw technical accounting and financial reporting through 2018.
- Ms. Crennen began her career as an auditor at PricewaterhouseCoopers, LLP in Denver.
- Ms. Crennen holds a B.S. degree in accounting and finance from the University of Colorado and is a Certified Public Accountant.
- She will be eligible to participate in the Company's short-term incentive bonus plan, with the opportunity to receive an annual cash bonus equal to 40% of her annual base salary, pursuant to the terms and conditions of such plan and subject to the achievement of performance targets set by the Compensation Committee of the Board.
- Ms. Crennen will also be eligible to participate in Mesa's long-term incentive plan with an annual target award value of $300,000, subject to the terms and conditions of the plan.
- The Employment Agreement contains customary severance and other terms.
Departing: Gary Owens, Director, effective 2026-03-20
In connection with the execution of the Transition Agreement, Mr. Owens also resigned as a member of the Company's board of directors (the "Board"), effective as of March 20, 2026.
- On March 9, 2026, Mesa Laboratories, Inc. ("Mesa" or the "Company") announced the departure of Gary Owens as President and Chief Executive Officer of the Company, effective on or about April 13, 2026.
- On March 20, 2026, Mr. Owens and the Company entered into a Retention and Transition Agreement (the "Transition Agreement") pursuant to which he will remain with the Company in a non-executive capacity until June 22, 2026 (the "Separation Date") to facilitate the transition of his role to his successor.
- As a condition to receiving the severance pay and benefits, Mr. Owens will be required to execute a release of claims in favor of the Company.
- Mr. Owens' resignation from the Board is not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
Departing: Gary Owens, President and Chief Executive Officer
CEO Departure On March 3, 2026, Mesa Laboratories, Inc. ("Mesa" or the "Company") initiated a leadership transition pursuant to which Gary Owens will depart as President and Chief Executive Officer of the Company, effective on or about April 13, 2026 (the "Transition Date").
Appointed: Siddhartha Kadia, President and Chief Executive Officer
CEO Appointment; Director Appointment In connection with Mr. Owens' departure, the Board has appointed Dr. Siddhartha Kadia to serve as the Company's new President and Chief Executive Officer, effective on or about April 13, 2026 (the "Effective Date").
- The terms of Mr. Owens' separation are in the process of being determined.
- Dr. Kadia's appointment was made after a comprehensive external search conducted by the Board as part of its CEO succession process and long-term leadership strategy.
- The Board has also approved the appointment of Dr. Kadia as a member of the Board, effective as of the Effective Date.
- Dr. Kadia, age 56, is an experienced executive with over 20 years in the life sciences, diagnostics and biotechnology sectors.
- Since January 2025, Dr. Kadia has served as Chief Executive Officer of Calibre Scientific, a diversified global provider of life science reagents, tools, instruments, and other consumables to the lab research, diagnostics and biopharmaceutical communities.
- From March 2022 to August 2023, he served as Chief Executive Officer of PhenomeX and its predecessor Berkeley Lights until its acquisition by Bruker Corporation.
- From 2014 to 2018, he served as Chief Executive Officer of EAG Laboratories.
- From 2005 to 2014, he served in various roles at Life Technologies (formerly Invitrogen Corporation), including President of the company's Life Sciences Division, until the company was acquired by Thermo Fisher Scientific.
- Dr. Kadia began his career at consultancy firm McKinsey & Company, where he worked from 2001 to 2005.
Tools for this story
Each opens in a new tab, filled in for Mesa Laboratories Inc /Co/. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
